Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America.

By G. Talbot, J. Bradley, J. Edwards, D. Gilbert, M. Scheld, J. Bartlett. Clinical Infectious Diseases, 2006

1,127 citations recorded by the source corpus.

Subfields: Applied Microbiology and Biotechnology, Clinical Biochemistry, Immunology

View Paper: https://www.semanticscholar.org/paper/ddca485b10abdca82b8a1313b22c8031880eebcb

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Applied Microbiology and Biotechnology

1. J. Pitout
2. S. Levy
3. David L. Paterson
4. A. Alanis

In Clinical Biochemistry

1. J. Pitout
2. Robert S. Daum
3. Michael Z. David
4. L. Rice
5. H. Boucher

In Immunology

1. S. Levy
2. Jian Li

Citations in the corpus

• The Role of Epidemic Resistance Plasmids and International High-Risk Clones in the Spread of Multidrug-Resistant Enterobacteriaceae (2015, background): “coli is an important component among global multidrug resistant bacteria and should be regarded as a major target for surveillance, infection control and fundamental investigations in the field of antimicrobial drug resistance (21).”
• Antibiotics and Bacterial Resistance in the 21st Century (2014, background): “Quinolones Balafloxacin, gemifloxacin, pazufloxacin, prulifloxacin Avarofloxacin (65), delafloxacin (63), finafloxacin (66), JNJ-Q2, levonadifloxacin, nemonoxacin (64)”
• The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. (2008, neutral): “to raise public awareness about the problem [43].”
• Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically Ill Patients from a Multicenter Study Provide Dosing Suggestions for Various Categories of Patients (2011, background): “With a paucity of new drugs available to treat infections caused by these MDR organisms, colistin, also known as polymyxin E, which was first introduced in the late 1950s, has reemerged as a treatment of choice and often as the only antibiotic active against these organisms (14, 26, 33).”
• The biology and future prospects of antivirulence therapies (2008, background): “However, the commercialization of new classes of antibiotics over the past 20 years has not met expectations, and current pharmaceutical pipelines lack new, broad-spectrum antibiotic”
• Acinetobacter baumannii: Emergence of a Successful Pathogen (2008, background): “The dearth of antibiotics, especially for gram-negative organisms, has recently stimulated attention from major research and governing bodies (388, 531).”
• Acinetobacter baumannii: evolution of a global pathogen. (2014, background): “…by the Infectious Diseases Society of America as one of the six most important multidrug-resistant (MDR) microorganisms in hospitals worldwide (Talbot et al., 2006) The genus Acinetobacter has undergonemany taxonomic changes over the years, and the species A. baumannii was not formally…”
• Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. (2009, background): “Because no comprehensive survey of antibiotic development was undertaken before the IDSA’s reports of 2004 and 2006 [12, 14], we cannot determine whether the 388 medications and vaccines reported in development by PhRMA—or even just the new, systemic antibacterials listed in the present…”
• Community-Associated Methicillin-Resistant Staphylococcus aureus: Epidemiology and Clinical Consequences of an Emerging Epidemic (2010, background): “Moreover, the available agents have important limitations, and the development of new antibiotic classes has slowed (882, 994).”
• Colistin and its role in the Era of antibiotic resistance: an extended review (2000–2019) (2020, methodology): “polymyxins were used to fight infections caused by intractable GNB [7,13].”